Growth Drivers
What could change its growth trajectory, and what would confirm it?
Reunion plans a pivotal Phase 3 postpartum depression trial in 2026 after RECONNECT met its Phase 2 primary endpoint with a statistically significant MADRS reduction at Day 7 that persisted through Day 28, and after the FDA aligned with it on a registrational path for luvesilocin in PPD; a successful Phase 3 result could support luvesilocin registration.
The REKINDLE Phase 2 trial is evaluating RE104 for adjustment disorder in patients with cancer and other medical illnesses, with topline data expected in the first quarter of 2027. RE245, a non-psychedelic serotonergic neuroplastogen, has an IND planned in 2026 and a Phase 1 trial planned in 2027.
Risk Factors
Which risks could break the thesis, and what would warn of them?
The registration case hinges on the planned Phase 3 trial of luvesilocin for postpartum depression: Reunion expects to begin the pivotal trial in 2026, and a successful result could support registration, while the Phase 2 result and the Breakthrough Therapy Designation precede that pivotal test. RECONNECT met its primary endpoint, with a statistically significant reduction in MADRS score on Day 7 and improvement through Day 28.
The FDA's Breakthrough Therapy Designation for luvesilocin was based on positive RECONNECT Phase 2 clinical data.
Product Overview
What does the product do for its buyer, and how is it delivered?
Reunion Neuroscience's pipeline lets clinicians treat postpartum depression and chronic mental-health conditions with investigational serotonergic options delivered as a subcutaneous short-duration prodrug or an oral non-psychedelic agonist. The FDA granted Breakthrough Therapy Designation to luvesilocin (formerly RE104) for postpartum depression. Luvesilocin is a 4-OH-DiPT prodrug delivered by subcutaneous injection, and single RE104 doses produced a 3-to-4-hour psychoactive experience with a safety profile similar to psilocybin.
RE245 is a discovery-stage non-psychedelic asset designed as an orally bioavailable 5HT2A agonist for chronic conditions without hallucinations or cardiotoxicity. Existing antidepressants such as SSRIs can have slow onset and require chronic dosing to relieve symptoms and prevent relapse.
